BioMérieux's molecular cancer diagnosis spinoff has agreed to a $230m purchase by women's health-focused Hologic.

Women’s health technology provider Hologic has agreed to acquire Biotheranostics, a US-based cancer-focused molecular diagnostics technology developer spun off by biotechnology firm BioMérieux, for about $230m. Founded in 2008, Biotheranostics supplies clinicians with molecular tests to inform cancer diagnoses. Its ests leverage a DNA sample copying-method called polymerase chain reaction to investigate gene expression signatures…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.